Reported about 18 hours ago
H.C. Wainwright has rated Akebia Therapeutics (NASDAQ:AKBA) as a ‘Buy’ with a target price of $8, driven by confidence in its drug Vafseo (vadadustat) for treating anemia in CKD patients on dialysis. Following FDA approval in March 2024, Vafseo became available in January 2025, and Akebia plans a Phase 3 trial for non-dialysis patients as it seeks broader market acceptance. Analysts foresee growth for the company as Vafseo gains traction among dialysis organizations.
Source: YAHOO